{
    "info": {
        "nct_id": "NCT04157985",
        "official_title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
        "inclusion_criteria": "* All patients must have an advanced solid tumor malignancy (specifically NSCLC, bladder, HNSCC, renal, melanoma, cervical, Merkel cell, MMR/MSI [colon, rectal, cholangio, esophageal, ovarian, uterine], anal, gastric and GE junction, hepatocellular, triple negative breast cancer) that is being treated with a PD-1/PD-L1 inhibitor including pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab according to standard of care treatment.\n* Patients who initially started treatment with another agent in combination with the PD-1/PD-L1 inhibitor, i.e. chemotherapy, ipilumumab, are eligible.\n* Patients must have at least stable disease as evidenced by scans performed within 6 weeks of randomization.\n* Signed Informed consent allowing randomization to stopping immunotherapy at 1 year ± 6 weeks versus continued treatment beyond 1 year.\n* Patients can have measurable or non-measurable disease per RECIST v1.1.\n* Patients cannot be enrolled in a clinical trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with documented progressive disease prior to randomization.\n* Patients with an immune-related toxicity preventing the continuation of treatment beyond 1 year at the treating physician's discretion.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients must have an advanced solid tumor malignancy (specifically NSCLC, bladder, HNSCC, renal, melanoma, cervical, Merkel cell, MMR/MSI [colon, rectal, cholangio, esophageal, ovarian, uterine], anal, gastric and GE junction, hepatocellular, triple negative breast cancer) that is being treated with a PD-1/PD-L1 inhibitor including pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab according to standard of care treatment.",
            "criterions": [
                {
                    "exact_snippets": "advanced solid tumor malignancy (specifically NSCLC, bladder, HNSCC, renal, melanoma, cervical, Merkel cell, MMR/MSI [colon, rectal, cholangio, esophageal, ovarian, uterine], anal, gastric and GE junction, hepatocellular, triple negative breast cancer)",
                    "criterion": "solid tumor malignancy",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "cancer_type",
                            "expected_value": [
                                "NSCLC",
                                "bladder",
                                "HNSCC",
                                "renal",
                                "melanoma",
                                "cervical",
                                "Merkel cell",
                                "MMR/MSI (colon, rectal, cholangio, esophageal, ovarian, uterine)",
                                "anal",
                                "gastric and GE junction",
                                "hepatocellular",
                                "triple negative breast cancer"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "being treated with a PD-1/PD-L1 inhibitor including pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab according to standard of care treatment",
                    "criterion": "PD-1/PD-L1 inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug_names",
                            "expected_value": [
                                "pembrolizumab",
                                "nivolumab",
                                "atezolizumab",
                                "durvalumab",
                                "avelumab"
                            ]
                        },
                        {
                            "requirement_type": "treatment_standard",
                            "expected_value": "standard of care"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have at least stable disease as evidenced by scans performed within 6 weeks of randomization.",
            "criterions": [
                {
                    "exact_snippets": "at least stable disease as evidenced by scans",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "stable disease"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "scans performed within 6 weeks of randomization",
                    "criterion": "scan timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who initially started treatment with another agent in combination with the PD-1/PD-L1 inhibitor, i.e. chemotherapy, ipilumumab, are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Patients who initially started treatment with another agent in combination with the PD-1/PD-L1 inhibitor, i.e. chemotherapy, ipilumumab",
                    "criterion": "prior treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "combination therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "PD-1/PD-L1 inhibitor included",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "other agent included",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed Informed consent allowing randomization to stopping immunotherapy at 1 year ± 6 weeks versus continued treatment beyond 1 year.",
            "criterions": [
                {
                    "exact_snippets": "Signed Informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients can have measurable or non-measurable disease per RECIST v1.1.",
            "criterions": [
                {
                    "exact_snippets": "measurable or non-measurable disease per RECIST v1.1.",
                    "criterion": "disease measurability (per RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "non-measurable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients cannot be enrolled in a clinical trial.",
            "criterions": [
                {
                    "exact_snippets": "Patients cannot be enrolled in a clinical trial.",
                    "criterion": "enrollment in a clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with documented progressive disease prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "documented progressive disease prior to randomization",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with an immune-related toxicity preventing the continuation of treatment beyond 1 year at the treating physician's discretion.",
            "criterions": [
                {
                    "exact_snippets": "immune-related toxicity preventing the continuation of treatment beyond 1 year",
                    "criterion": "immune-related toxicity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "prevents continuation of treatment beyond 1 year"
                        }
                    ]
                },
                {
                    "exact_snippets": "at the treating physician's discretion",
                    "criterion": "treating physician's discretion",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}